Search fresh public links, source activity, and ready-to-use post angles for Rtk/Ras Pathway.
Fresh curated links around RTK/RAS pathway are collected here so marketers can spot useful updates and turn timely ideas into posts faster.
Recent items include:
Recent curated links from global sources. Generate one free draft from any story, then use SocialBu to schedule and refine your content calendar.
KRAS has long been one of cancer biology’s most stubborn molecular targets. The protein acts as a switch that helps cells interpret growth signals, cycling between an active state...
Mutant NRAS has remained difficult to target in cancer. New findings suggest that its signaling partnership with wild-type HRAS may offer a targetable vulnerability, but effective...
A Huntsman Cancer Institute team at the University of Utah reports that daraxonrasib, a targeted RAS inhibitor, could offer a new treatment route for a subset of melanoma patients...
Cancer cells may be able to reprogram more than gene activity and signaling networks. A study led by researchers at Fudan University and Zhongshan Hospital in Shanghai reports that...
Daraxonrasib, Revolution Medicines tarafından geliştirilen deneysel bir oral RAS inhibitörü, ameliyat dışı NSCLC olgularının yaklaşık üçte birini oluşturan ve PD-1 ek...
In papillary thyroid carcinoma (PTC), cancer progression is increasingly understood as a product of two intertwined signaling engines: MAPK and PI3K/AKT. While these pathways norma...
Ras, one of the cell’s most influential molecular switches, has become the focus of a new live-cell imaging technology designed to reveal where and when the protein is active. In a...
Today, the U.S. Food and Drug Administration approved daraxonrasib (Rasonque), a groundbreaking new drug for pancreatic cancer that targets the RAS family of proteins. Catch up on...
The AACR D3 edition of “From the Bench” highlights cutting-edge approaches from the meeting that could shape the next generation of cancer treatments. We spoke with Andrea Wang-Gil...
Following dynamite data that earned a standing ovation at the American Society of Clinical Oncology meeting in May, Revolution Medicines’ Ras inhibitor daraxonrasib has been approv...
FDA approval of Revolution Medicines’ daraxonrasib, brand name Rasonque, makes the molecule the first RAS inhibitor approved for treating pancreatic adenocarcinoma, the most common...
In a groundbreaking development for appendix cancer treatment, researchers at The University of Texas MD Anderson Cancer Center have unveiled promising results targeting the mutant...
Use SocialBu to discover ideas, generate post drafts, and schedule them across your social channels.